Gambaran Umum
Theriva Biologics, Inc., a biopharmaceutical company based in the United States, operates primarily in the healthcare sector, specializing in the development of novel therapeutics for significant unmet medical needs. The company is actively engaged in pioneering projects, including the research and development of biologic treatments that target both oncologic and gastrointestinal conditions. A key area of focus for Theriva Biologics is enhancing the efficacy and safety of treatment options for patients suffering from debilitating diseases, working closely with regulatory bodies to advance their clinical trials. Their comprehensive approach integrates cutting-edge scientific methodologies with stringent regulatory compliance to drive innovation in therapy development and delivery.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai operating income untuk Theriva Biologics, Inc. per 2025 Jun 30 adalah -26.39 MM.
- Nilai net income untuk Theriva Biologics, Inc. per 2025 Jun 30 adalah -29.55 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | -26.39 | -29.55 | |
2025-03-31 | -17.93 | -24.81 | |
2024-12-31 | -18.73 | -25.65 | |
2024-09-30 | -20.21 | -26.69 | |
2024-06-30 | -21.55 | -22.27 | |
2024-03-31 | -22.10 | -19.04 | |
2023-12-31 | -22.09 | -18.35 | |
2023-09-30 | -21.44 | -19.31 | |
2023-06-30 | -20.44 | -20.50 | |
2023-03-31 | -20.22 | -19.89 | |
2022-12-31 | -19.29 | -19.68 | |
2022-09-30 | -19.33 | -18.50 | |
2022-06-30 | -17.82 | -17.29 | |
2022-03-31 | -15.99 | -16.00 | |
2021-12-31 | -14.27 | -14.27 | |
2021-09-30 | -11.14 | -11.11 | |
2021-06-30 | -9.98 | -9.94 | |
2021-03-31 | -9.67 | -9.62 | |
2020-12-31 | -10.16 | -10.04 | |
2020-09-30 | -11.24 | -11.07 | |
2020-06-30 | |||
2020-03-31 |
Laporan Laba Rugi: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | -19.03 | |
2024-09-30 | -32.52 | -32.52 |
2024-06-30 | -31.50 | -31.50 |
2024-03-31 | -28.65 | -28.65 |
2023-12-31 | -28.48 | |
2023-09-30 | -30.58 | -30.58 |
2023-06-30 | -33.65 | -33.65 |
2023-03-31 | -32.31 | -32.31 |
2022-12-31 | -32.66 | |
2022-09-30 | -32.08 | -32.08 |
2022-06-30 | -30.80 | -30.80 |
2022-03-31 | -29.92 | -29.92 |
2021-12-31 | -47.57 | |
2021-09-30 | -55.90 | -55.90 |
2021-06-30 | -77.61 | -77.61 |
2021-03-31 | -137.46 | -137.46 |
2020-12-31 | -165.13 | |
2020-09-30 | -175.42 | -175.42 |
2020-06-30 | -219.14 | -219.14 |
2020-03-31 | -231.21 | -231.21 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Theriva Biologics, Inc. per 2025 Jun 30 adalah -18.07 MM.
- Nilai cash from investing activities untuk Theriva Biologics, Inc. per 2025 Jun 30 adalah -0.02 MM.
- Nilai kas dari aktivitas pendanaan untuk Theriva Biologics, Inc. per 2025 Jun 30 adalah 13.61 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -18.07 | -0.02 | 13.61 |
2025-03-31 | -16.81 | -0.00 | 8.57 |
2024-12-31 | -16.94 | -0.00 | 5.50 |
2024-09-30 | -18.79 | -0.06 | 4.03 |
2024-06-30 | -17.83 | -0.19 | 0.32 |
2024-03-31 | -18.27 | -0.19 | 0.68 |
2023-12-31 | -19.00 | -0.20 | 0.62 |
2023-09-30 | -17.82 | -0.24 | -1.21 |
2023-06-30 | -19.33 | -0.12 | 1.53 |
2023-03-31 | -19.79 | -0.12 | -0.61 |
2022-12-31 | -19.08 | -4.40 | -1.93 |
2022-09-30 | -18.52 | -4.30 | 1.36 |
2022-06-30 | -16.22 | -4.29 | -1.38 |
2022-03-31 | -14.46 | -4.28 | -1.38 |
2021-12-31 | -12.89 | -0.01 | 74.00 |
2021-09-30 | -11.21 | -0.02 | 77.36 |
2021-06-30 | -11.11 | -0.02 | 77.36 |
2021-03-31 | -10.54 | -0.02 | 77.36 |
2020-12-31 | -12.17 | -0.01 | 3.36 |
2020-09-30 | -12.64 | -0.00 | |
2020-06-30 | |||
2020-03-31 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 | |||
2020-06-30 | |||
2020-03-31 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | ||
2024-06-30 | ||
2024-03-31 | ||
2023-12-31 | ||
2023-09-30 | ||
2023-06-30 | ||
2023-03-31 | ||
2022-12-31 | ||
2022-09-30 | ||
2022-06-30 | ||
2022-03-31 | ||
2021-12-31 | ||
2021-09-30 | ||
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 | ||
2020-09-30 | ||
2020-06-30 | ||
2020-03-31 |
Efektivitas Manajemen
- roa untuk Theriva Biologics, Inc. pada 2025 Jun 30 adalah -0.59.
- roe untuk Theriva Biologics, Inc. pada 2025 Jun 30 adalah -0.90.
- roic untuk Theriva Biologics, Inc. pada 2025 Jun 30 adalah -1.35.
- croic untuk Theriva Biologics, Inc. pada 2025 Jun 30 adalah -0.45.
- ocroic untuk Theriva Biologics, Inc. pada 2025 Jun 30 adalah -0.92.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -0.59 | -0.90 | -1.35 | -0.45 | -0.92 |
2025-03-31 | -0.53 | -0.73 | -1.24 | -0.56 | -0.82 |
2024-12-31 | -0.48 | -0.65 | -1.01 | -0.56 | -0.71 |
2024-09-30 | -0.36 | -0.61 | -0.76 | -0.60 | -0.60 |
2024-06-30 | -0.28 | -0.38 | -0.53 | -0.49 | -0.51 |
2024-03-31 | -0.26 | -0.34 | -0.44 | -0.44 | -0.45 |
2023-12-31 | -0.25 | -0.33 | -0.42 | -0.42 | -0.39 |
2023-09-30 | -0.25 | -0.33 | -0.41 | -0.36 | -0.39 |
2023-06-30 | -0.25 | -0.33 | -0.41 | -0.36 | -0.39 |
2023-03-31 | -0.22 | -0.29 | -0.37 | -0.39 | -0.37 |
2022-12-31 | -0.26 | -0.27 | -0.32 | -0.36 | -0.31 |
2022-09-30 | -0.26 | -0.27 | -0.32 | -0.36 | -0.31 |
2022-06-30 | -0.23 | -0.24 | -0.28 | -0.35 | -0.26 |
2022-03-31 | -0.20 | -0.21 | -0.23 | -0.29 | -0.21 |
2021-12-31 | -1.70 | -2.71 | -0.21 | 0.91 | -0.19 |
2021-09-30 | -1.54 | -2.83 | -0.15 | 0.92 | -0.16 |
2021-06-30 | -1.04 | -1.71 | -0.13 | 0.88 | -0.15 |
2021-03-31 | -0.81 | -1.12 | -0.12 | 0.86 | -0.14 |
2020-12-31 | -0.58 | -0.87 | -1.75 | -1.54 | -2.12 |
2020-09-30 | -0.53 | -0.76 | -2.48 | -2.83 | -2.83 |
2020-06-30 | -0.59 | -0.72 | -2.19 | -2.13 | -2.13 |
2020-03-31 | -0.55 | -0.64 | -1.59 | -1.58 | -1.58 |
Gross Margins
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 | |||
2020-06-30 | |||
2020-03-31 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 894158 |
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations |